ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,724.30
-0.33%
S&P ASX All Technology
3,092.70
-1.13%
Brent Oil
82.275
0.00%
US Dollar vs AUD
1.51378
0.08%
Bitcoin
66,163.61
0.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) News

RPRX

Royalty Pharma (RPRX)

Royalty Pharma PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RPRX
DateTimeSourceHeadlineSymbolCompany
11/06/202406:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
07/06/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
05/06/202407:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPRXRoyalty Pharma PLC
05/06/202406:57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
05/06/202406:15GlobeNewswire Inc.Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
04/06/202407:15GlobeNewswire Inc.Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured NotesNASDAQ:RPRXRoyalty Pharma PLC
04/06/202406:59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202423:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPRXRoyalty Pharma PLC
03/06/202422:39Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RPRXRoyalty Pharma PLC
30/05/202407:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
28/05/202421:10GlobeNewswire Inc.Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionNASDAQ:RPRXRoyalty Pharma PLC
23/05/202406:10GlobeNewswire Inc.Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
23/05/202406:00GlobeNewswire Inc.Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
17/05/202407:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RPRXRoyalty Pharma PLC
13/05/202422:15GlobeNewswire Inc.Royalty Pharma to Present at Upcoming Investor ConferencesNASDAQ:RPRXRoyalty Pharma PLC
09/05/202423:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPRXRoyalty Pharma PLC
09/05/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
09/05/202421:00GlobeNewswire Inc.Royalty Pharma Reports First Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
09/05/202420:45GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Sanofi’s FrexalimabNASDAQ:RPRXRoyalty Pharma PLC
19/04/202422:15GlobeNewswire Inc.Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:RPRXRoyalty Pharma PLC
17/04/202422:15GlobeNewswire Inc.Royalty Pharma Declares Second Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
29/02/202408:15GlobeNewswire Inc.Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:RPRXRoyalty Pharma PLC
16/02/202401:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RPRXRoyalty Pharma PLC
15/02/202423:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
15/02/202423:30GlobeNewswire Inc.Royalty Pharma Reports Q4 and Full Year 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
06/02/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
31/01/202408:15GlobeNewswire Inc.Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024NASDAQ:RPRXRoyalty Pharma PLC
20/01/202400:15GlobeNewswire Inc.Royalty Pharma Announces Dividend IncreaseNASDAQ:RPRXRoyalty Pharma PLC
08/01/202423:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
08/01/202423:00GlobeNewswire Inc.Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:RPRX

Your Recent History

ASX
CBA
Commonwealth Bank Of Aus...
ASX
AMP
AMP
ASX
NAB
National Australia Bank
NYSE
DIS
Walt Disney
ASX
NCM
Newcrest Mining
ASX
CSL
CSL
ASX
RIO
Rio Tinto
FX
AUDJPY
AUD vs Yen
ASX
WBC
Westpac Banking
NYSE
KO
Coca Cola
ASX
MQG
Macquarie
ASX
XTO
S&P ASX 100
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
ASX
XMM
S&P ASX 300 Metals and M...
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved